Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP8 | P40818 | 1/20 | 0.35 |
| ▸ | USP7 | Q93009 | 1/20 | 0.35 |
| ▸ | DAO | P14920 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.32 |
| ▸ | EGLN2 | Q96KS0 | 2/20 | 0.31 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.30 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29368821 | 1.00 | USP8 (0.35) | USP8USP7DAOKDM4EALDH1A1 | |
| SCHEMBL7585113 | 0.80 | KDM4E (0.35) | KDM4EALDH1A1POLBEGLN2CYP11B1 | |
| SCHEMBL24424865 | 0.80 | KDM4E (0.46) | USP8USP7DAOKDM4EALDH1A1 | |
| SCHEMBL34468447 | 0.80 | USP8 (0.33) | USP8USP7DAOKDM4EALDH1A1 | |
| SCHEMBL2596849 | 0.79 | KDM4E (0.32) | KDM4EALDH1A1POLBEGLN2 | |
| SCHEMBL24455335 | 0.79 | KDM4E (0.33) | KDM4EALDH1A1POLBCYP11B1CYP11B2 | |
| SCHEMBL29877981 | 0.73 | KDM4E (0.32) | KDM4EALDH1A1POLB | |
| SCHEMBL16923273 | 0.72 | PIK3CD (0.34) | KDM4EALDH1A1POLB | |
| SCHEMBL16769277 | 0.71 | CYP11B1 (0.40) | USP8USP7KDM4EALDH1A1POLB | |
| SCHEMBL25559596 | 0.71 | CHEK1 (0.37) | USP8USP7KDM4EALDH1A1CYP11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11466027-B2 | Modulators of the NMDA receptor | H. LUNDBECK A/S (DK) | 2022-10-11 | — | — | US | disclosed |
| US-20220213117-A1 | PRODRUGS OF MODULATORS OF THE NMDA RECEPTOR | H. LUNDBECK A/S (DK) | 2022-07-07 | — | — | US | disclosed |
| US-11358971-B2 | Prodrugs of modulators of the NMDA receptor | H. LUNDBECK A/S (DK) | 2022-06-14 | — | — | US | disclosed |
| CN-114008054-A | NMDA receptor modulators | H.隆德贝克有限公司 | 2022-02-01 | — | — | CN | disclosed |
| CN-114008053-A | Prodrugs of NMDA receptor modulators | H.隆德贝克有限公司 | 2022-02-01 | — | — | CN | disclosed |
| US-11236046-B2 | Substituted heterocyclic sulfonamide compounds useful as TRPA1 modulators | GENENTECH, INC. (US) | 2022-02-01 | — | — | US | disclosed |
| US-20210047342-A1 | PRODRUGS OF MODULATORS OF THE NMDA RECEPTOR | H. LUNDBECK A/S (DK) | 2021-02-18 | — | — | US | disclosed |
| WO-2021001420-A1 | PRODRUGS OF MODULATORS OF THE NMDA RECEPTOR | H. LUNDBECK A/S (DK) | 2021-01-07 | — | — | WO | disclosed |
| US-20210002292-A1 | MODULATORS OF THE NMDA RECEPTOR | H. LUNDBECK A/S (DK) | 2021-01-07 | — | — | US | disclosed |
| WO-2021001423-A1 | MODULATORS OF THE NMDA RECEPTOR | H. LUNDBECK A/S (DK) | 2021-01-07 | — | — | WO | disclosed |
| US-20200048197-A1 | SUBSTITUTED HETEROCYCLIC SULFONAMIDE COMPOUNDS USEFUL AS TRPA1 MODULATORS | GENENTECH, INC. (US) | 2020-02-13 | — | — | US | disclosed |
| US-20180118680-A1 | SUBSTITUTED HETEROCYCLIC SULFONAMIDE COMPOUNDS USEFUL AS TRPA1 MODULATORS | GENENTECH, INC. (US) | 2018-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11466027-B2 | Modulators of the NMDA receptor | GRIN1, GRIN2A, GRIN3A | USP8 4142/4885USP7 4250/4885DAO 809/4885 |
| US-20180118680-A1 | SUBSTITUTED HETEROCYCLIC SULFONAMIDE COMPOUNDS USEFUL AS TRPA1 MODULATORS | TRPA1, TRPV1, TRPV2 | USP8 3888/4885USP7 4270/4885DAO 3159/4885 |
| US-11358971-B2 | Prodrugs of modulators of the NMDA receptor | GRIN3A, GRIN1, GRIN2A | USP8 2982/4885USP7 3729/4885DAO 564/4885 |
| US-20200048197-A1 | SUBSTITUTED HETEROCYCLIC SULFONAMIDE COMPOUNDS USEFUL AS TRPA1 MODULATORS | TRPA1, TRPV1, TRPV2 | USP8 3888/4885USP7 4270/4885DAO 3159/4885 |
| US-20210002292-A1 | MODULATORS OF THE NMDA RECEPTOR | GRIN1, GRIN2A, GRIN3A | USP8 4142/4885USP7 4250/4885DAO 809/4885 |
| US-20210047342-A1 | PRODRUGS OF MODULATORS OF THE NMDA RECEPTOR | GRIN3A, GRIN1, GRIN2A | USP8 2982/4885USP7 3729/4885DAO 564/4885 |
| US-11236046-B2 | Substituted heterocyclic sulfonamide compounds useful as TRPA1 modulators | TRPA1, TRPV1, TRPV2 | USP8 3888/4885USP7 4270/4885DAO 3159/4885 |
| US-20220213117-A1 | PRODRUGS OF MODULATORS OF THE NMDA RECEPTOR | GRIN3A, GRIN1, GRIN2A | USP8 2982/4885USP7 3729/4885DAO 564/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.